Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 6

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Human myoglobin and its diagnostic value

100%
Szewczuk A., Kochanowska I. E.
Postępy Higieny i Medycyny Doświadczalnej
|
1995
|
vol. 49
|
issue 3
343-352
EN
Composition, properties and occurence of human myoglobin (hMb) were described.Methods for immunological assay of hMb were persented.Localization of antigenic determinants in myoglobin molecule was shown.Value of assay of hMb in serum and urine for early diagnosis of myocardial infarct and some other muscle dieases was discussed.
2

Immuno-contraception vaccines

100%
Kochanowska I. E., Szewczuk A.
Postępy Higieny i Medycyny Doświadczalnej
|
1995
|
vol. 49
|
issue 4
441-468
EN
Results of studies on birth control vaccines acomplished by many research groups within the WHO Special Programme of Research, Development and Research Training in Human Reproduction has been reviewed.The mostly investigated contraceptive vaccines contain human chorionic gonadotropin, and therefore structure, biological role and immunogenecity of the hormone were presented.Also vaccines obtained on teh basis of subunit beta of the human chorionic gonadotropin, its heterodimer with subunit beta of ovine lutropin or C-terminal peptide of beta subunit were described.Results of two phases of clinical trials with immuno-contraceptive vaccines were persented.The use of contraceptive vaccines for treatment of some trophoblastic tumors and the idea of using contraceptive recombinant vaccines were also mentioned.
3

Luteinizing hormone isoforms

81%
Szewczuk A., Kochanowska I. E., Kurowska E.
Postępy Higieny i Medycyny Doświadczalnej
|
1996
|
vol. 50
|
issue 1
9-20
EN
Luteinizing hormone (LH) is a heterodimeric glycoprotein containing varied amount of sialic acid. This is a reason of numerous LH isoforms called also isohormones. The hormone isoforms were separated usually by gelelectrophoresis, isoelectrofocusing or chromatofocusing. They differ in biological and immunological activity. Human and some animals LH isoforms were reviewed. Also some genetic mutants of LH are described. Problems of the human isoforms for pathology and diagnostics are presented.
4

Human luteinizing hormone (hLH)

81%
Szewczuk A., Kochanowska I. E., Kurowska E.
Postępy Higieny i Medycyny Doświadczalnej
|
1994
|
vol. 48
|
issue 5
491-504
EN
Heterodimeric composition and amino acid sequence of hLH is reviewed.The hormone isoforms and methods of their assay are sumarized.Releasing of the hormone, its control by synthetic antagonists and agonists and their sigificance for therapy are described.Structure and function of hLH receptor are presented.
5

The soluble CTLA-4 receptor: a new marker in autoimmune diseases

61%
Pawlak E., Kochanowska I. E., Frydecka I., Kielbinski M., Potoczek S., Bilinska M.
Archivum Immunologiae et Therapiae Experimentalis
|
2005
|
vol. 53
|
issue 4
336-341
EN
A soluble form of cytotoxic T lymphocyte-associated antigen-4 (sCTLA-4) was recently found and shown to possess B7 binding activity. sCTLA-4 is generated by alternatively spliced mRNA. The mRNA encoding sCTLA-4 consists of 3 exons: exon 1 encodes a leader peptide, exon 2 the ligand binding domain, and exon 4 the cytoplasmic tail, but it lacks the transmembrane domain encoded by exon 3. The altered transcript is detected in resting CD4 and CD8 T cells and its expression is inhibited after 24?48 h of activation and returns to the prestimulation level after 72?120 h of activation. Low levels of sCTLA-4 have been detected in normal human serum and increased serum levels have been observed in several autoimmune diseases (e.g. Graves' disease, myasthenia gravis, systemic lupus erythematosus, and systemic sclerosis). The biological significance of increased sCTLA-4 serum level has not been clarified. On one hand, sCTLA-4 may bind B7 expressed on antigen-presenting cells and is thus able to interfere with the B7:CD28-mediated costimulation of T cell responses. On the other hand, sCTLA-4 may also be capable of interfering with B7:CTLA-4 interactions, thereby blocking the negative signal imparted via the full-length form of CTLA-4. This double-edged nature of B7 blocking by sCTLA-4 may result in different outcomes of the clinical course of disease.
6

Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice

61%
Zagulski T., Jarzabek Z., Zagulska A., Jaszczak M., Kochanowska I. E., Zimecki M.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 6
431-438
EN
We have previously shown that bovine lactoferrin (BLF) given intravenously (i.v.) protected mice against a lethal dose of E. coli and strongly stimulated both the clearing and killing activities in liver, lungs, spleen and kidney. Since some studies indicated a reduction of the manifestation of experimental pancreatitis with lactoferrin, we decided to examine the protective activity of BLF against lethal E. coli infection in animals with alloxan (Alx)-induced diabetes. It appeared that 48 h diabetes substantially lowered the killing activity in all four organs as well as the clearing rate of E. coli from the circulation. BLF given i.v. o reduced this undesirable effect of diabetes. However, in 10- and 20-day diabetic animals, the diabetes alone stimulated the killing activity in the organs investigated, and upregulated the clearing rate of E. coli from the circulation. Lactoferrin (LF) significantly increased both the killing and the clearing activity in these long-term diabetic animals. In some cases the stimulating effect of BLF was very high, suggesting a concerted action of BLF and diabetes in that category of mice. Despite these beneficial effects of BLF and diabetes on the killing process in the investigated organs, the survival time of animals from all the diabetic groups ( 48 h, 10 and 20 days) was not prolonged by BLF. The protective properties of BLF did not depend on the blood glucose levels in the diabetic animals. BLF partly delayed the development of experimental Alx-induced diabetes, measured by the glucose level, but only if administered shortly after Alx injection. In conclusion, we demonstrated that the state of diabetes alone could increase killing of bacteria in the investigated organs and LF enhanced this process. However, LF had no protective effect against the mortality of diabetic mice infected with a lethal dose of E. coli.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.